Literature DB >> 11992542

Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the beta6 integrin subunit.

Jun Niu1, Douglas J Dorahy, Xinhua Gu, R J Scott, Brian Draganic, Nuzhat Ahmed, Michael V Agrez.   

Abstract

We have previously reported that the alphavbeta6 integrin upregulates its own expression in a protein kinase C-dependent manner with increasing cell density. The wild-type beta6 integrin subunit has also been shown to promote tumour growth in vivo and its growth-enhancing effect is regulated by both a MAP kinase binding motif on beta6 and the 11 amino acid C-terminal cytoplasmic extension unique to the beta6 subunit. Herein, we show that the 11 amino acid cytoplasmic extension is essential for the cell density-dependent increase in beta6 expression and that the 11 amino acid tail exerts a dominant negative effect on cell density- and PKC-mediated beta5 expression in alphavbeta6-expressing colon cancer cells. Cells that express beta6 lacking the 11 amino acid tail respond to PKC simulation with increased expression of only the beta5 subunit as seen for cells that lack constitutive alphavbeta6 expression. In contrast, loss of the ERK binding site on beta6 markedly impairs cell density- and PKC-dependent expression of either beta6 or beta5 in the presence or absence of the 11 amino acid tail, respectively. Our findings suggest that in alphavbeta6-expressing cells, a hierarchy of kinase signalling cascades exists and that the beta6-ERK2 interaction dominates over PKC-mediated signalling pathways responsible for integrin upregulation with cell confluence. Given the dominance of the beta6-ERK2 interaction over PKC-mediated expression of both beta5 and beta6 integrin subunits, targeting the beta6-ERK2 interaction may prove useful as an anticancer strategy in colon cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992542     DOI: 10.1002/ijc.10397

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes.

Authors:  Lu Qi; Marilyn C Cornelis; Peter Kraft; Kristopher J Stanya; W H Linda Kao; James S Pankow; Josée Dupuis; Jose C Florez; Caroline S Fox; Guillaume Paré; Qi Sun; Cynthia J Girman; Cathy C Laurie; Daniel B Mirel; Teri A Manolio; Daniel I Chasman; Eric Boerwinkle; Paul M Ridker; David J Hunter; James B Meigs; Chih-Hao Lee; Frank B Hu; Rob M van Dam
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

2.  Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy.

Authors:  Liu Enyu; Niu Zhengchuan; Wang Jiayong; Liang Benjia; Sun Qi; Qin Ruixi; Peng Cheng; Abdul Qadir Khan; Song Wei; Niu Jun
Journal:  Tumour Biol       Date:  2015-05-17

Review 3.  Defining the role of integrin alphavbeta6 in cancer.

Authors:  A Bandyopadhyay; S Raghavan
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

4.  Role of alphavbeta6 integrin in acute biliary fibrosis.

Authors:  Bruce Wang; Brian M Dolinski; Noriko Kikuchi; Diane R Leone; Marion G Peters; Paul H Weinreb; Shelia M Violette; D Montgomery Bissell
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

5.  Caveolin-1 tumor-promoting role in human melanoma.

Authors:  Federica Felicetti; Isabella Parolini; Lisabianca Bottero; Katia Fecchi; Maria Cristina Errico; Carla Raggi; Mauro Biffoni; Francesca Spadaro; Michael P Lisanti; Massimo Sargiacomo; Alessandra Carè
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

6.  miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.

Authors:  Nadia Felli; Federica Felicetti; Anna Maria Lustri; M Cristina Errico; Lisabianca Bottero; Alessio Cannistraci; Alessandra De Feo; Marina Petrini; Francesca Pedini; Mauro Biffoni; Ester Alvino; Massimo Negrini; Manuela Ferracin; Gianfranco Mattia; Alessandra Carè
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

7.  Why integrin as a primary target for imaging and therapy.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2011       Impact factor: 11.556

8.  Oxidative stress induced mechanisms in the progression of periodontal diseases and cancer: a common approach to redox homeostasis?

Authors:  Mena Soory
Journal:  Cancers (Basel)       Date:  2010-04-26       Impact factor: 6.639

9.  Targeting of the β6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.

Authors:  Yuhua Zhang; Lijing Wei; Jin Yu; Guang Li; Xiuru Zhang; Anliu Wang; Yanjiao He; Hongli Li; Deling Yin
Journal:  Oncol Rep       Date:  2014-08-20       Impact factor: 3.906

10.  Integrin β6 serves as an immunohistochemical marker for lymph node metastasis and promotes cell invasiveness in cholangiocarcinoma.

Authors:  Zequn Li; Siddhartha Biswas; Benjia Liang; Xueqing Zou; Liqun Shan; Yang Li; Ruliang Fang; Jun Niu
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.